Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
Breakingon.com is an independent news platform that delivers the latest news, trends, and analyses quickly and objectively. We gather and present the most important developments from around the world and local sources with accuracy and reliability. Our goal is to provide our readers with factual, unbiased, and comprehensive news content, making information easily accessible.
Stay informed with us!
